The growing support for nuclear power is compared to the rapid sentiment shift on gay marriage, driven by younger generations. As older activists, whose opposition was rooted in Cold War-era fears of nuclear weapons, fade away, a new generation sees nuclear energy as a key climate solution, creating a much more favorable political environment.

For new nuclear tech, competing with cheap solar on cost is a losing battle. The winning strategy is targeting "premium power" customers—like the military or hyperscalers—who have mission-critical needs for 24/7 clean, reliable energy and are willing to pay above market rates. This creates a viable beachhead market.

Startups can bypass the lengthy NRC process for initial reactor tests by using Department of Energy (DOE) and Department of Defense (DOD) pathways. The DOE, with national labs, can regulate test reactors for faster innovation. Crucially, the Army can now license its own reactors, creating a direct regulatory and commercial path to a key market.

While solar panels are inexpensive, the total system cost to achieve 100% reliable, 24/7 coverage is massive. These "hidden costs"—enormous battery storage, transmission build-outs, and grid complexity—make the final price of a full solution comparable to nuclear. This is why hyperscalers are actively pursuing nuclear for their data centers.

The massive energy consumption of AI has made tech giants the most powerful force advocating for new power sources. Their commercial pressure is finally overcoming decades of regulatory inertia around nuclear energy, driving rapid development and deployment of new reactor technologies to meet their insatiable demand.

Instead of tackling multiple downstream symptoms, identify and solve the single upstream "lead domino" problem. For example, making energy abundant and cheap through nuclear power makes complex challenges like recycling and carbon capture economically and technically feasible, rather than performative, inefficient gestures.

While the FDA is often blamed for high trial costs, a major culprit is the consolidated Clinical Research Organization (CRO) market. These entrenched players lack incentives to adopt modern, cost-saving technologies, creating a structural bottleneck that prevents regulatory modernization from translating into cheaper and faster trials.

Regulating technology based on anticipating *potential* future harms, rather than known ones, is a dangerous path. This 'precautionary principle,' common in Europe, stifles breakthrough innovation. If applied historically, it would have blocked transformative technologies like the automobile or even nuclear power, which has a better safety record than oil.

Introducing legislation in Congress isn't always about immediate passage. Bills frequently function as messaging vehicles to build awareness and support for an idea over several congressional terms. This gradual process allows for the evolution of major policy, like the creation of new government agencies, which rarely happens in a single two-year cycle.